|
|
 |
|
Viewing report
|
|
|
|
Challenges for a Maturing Biotechnology Industry: Evolve or Perish
Decision Resources, Inc, Aug 2007, Pages: 23
Today’s biotech industry is maturing and must now change the way it operates. The industry is facing significant challenges from operational, business, clinical development, and market risks. Business fundamentals, which many biotech companies have had the luxury to ignore, are now emerging as critical elements for sustainability and survival.
Get the Answers You Need to Shape Your Strategy
- Today’s biotech market is increasingly crowded and competitive. What can companies do to differentiate their products? What business fundamentals do they need to understand in order to plan a successful market strategy for their new products?
- Many successful biotech companies are surrendering their independence and merging with larger entities. What made these companies decide to give up their independence? Why have so many of them struggled even after launching blockbuster drugs?
- In the rush to develop a marketed product, many biotech companies are deficit spending. How do some companies manage to make deficit spending pay off? What makes others eventually collapse?
- Many biotechs have licensed away so many of the rights to their first products that they do not reap substantial financial rewards once the products launch. Which companies have made this mistake? Why did they make deals that left them financially vulnerable?
Scope
- Challenges facing the industry: operational, business, clinical development, and market risks.
- Business fundamentals: essential information biotechs need to run their business in today’s market.
- Deficit spending: case studies of how several biotechs handled deficit spending.
- Competing against crowded pipelines: effective strategies, case studies.
- Projections for the future: our projections on what the future holds for the biotech industry and its synergistic relationship with the pharmaceutical industry.
|
|
|
|
